MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
Moderna, Inc. MRNA announced the dosing of the first participant in the phase III Nova 301 study, which is evaluating its investigational mRNA norovirus vaccine candidate, mRNA-1403, in the United States.